X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs BIOCON LTD - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA BIOCON LTD GSK PHARMA/
BIOCON LTD
 
P/E (TTM) x 60.1 36.6 164.4% View Chart
P/BV x 11.8 4.9 242.6% View Chart
Dividend Yield % 2.1 1.5 137.5%  

Financials

 GSK PHARMA   BIOCON LTD
EQUITY SHARE DATA
    GSK PHARMA
Mar-16
BIOCON LTD
Mar-16
GSK PHARMA/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs3,850496 776.7%   
Low Rs2,966397 748.0%   
Sales per share (Unadj.) Rs332.3174.3 190.7%  
Earnings per share (Unadj.) Rs44.344.8 98.9%  
Cash flow per share (Unadj.) Rs47.256.9 83.0%  
Dividends per share (Unadj.) Rs50.005.00 1,000.0%  
Dividend yield (eoy) %1.51.1 130.9%  
Book value per share (Unadj.) Rs202.7202.8 100.0%  
Shares outstanding (eoy) m84.70200.00 42.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x10.32.6 400.6%   
Avg P/E ratio x76.910.0 772.7%  
P/CF ratio (eoy) x72.27.8 920.7%  
Price / Book Value ratio x16.82.2 764.1%  
Dividend payout %112.911.2 1,011.5%   
Avg Mkt Cap Rs m288,64389,220 323.5%   
No. of employees `0004.64.4 104.4%   
Total wages/salary Rs m4,4346,363 69.7%   
Avg. sales/employee Rs Th6,104.57,894.5 77.3%   
Avg. wages/employee Rs Th961.61,441.2 66.7%   
Avg. net profit/employee Rs Th813.72,029.7 40.1%   
INCOME DATA
Net Sales Rs m28,14834,854 80.8%  
Other income Rs m1,218845 144.2%   
Total revenues Rs m29,36635,699 82.3%   
Gross profit Rs m4,7748,200 58.2%  
Depreciation Rs m2482,423 10.2%   
Interest Rs m0102 0.0%   
Profit before tax Rs m5,7446,520 88.1%   
Minority Interest Rs m0-744 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m265,754 0.5%   
Tax Rs m2,0182,569 78.6%   
Profit after tax Rs m3,7528,961 41.9%  
Gross profit margin %17.023.5 72.1%  
Effective tax rate %35.139.4 89.2%   
Net profit margin %13.325.7 51.8%  
BALANCE SHEET DATA
Current assets Rs m21,46239,932 53.7%   
Current liabilities Rs m10,53616,276 64.7%   
Net working cap to sales %38.867.9 57.2%  
Current ratio x2.02.5 83.0%  
Inventory Days Days6854 126.3%  
Debtors Days Days1686 19.0%  
Net fixed assets Rs m4,71739,101 12.1%   
Share capital Rs m8471,000 84.7%   
"Free" reserves Rs m16,30838,591 42.3%   
Net worth Rs m17,17140,556 42.3%   
Long term debt Rs m1620,724 0.1%   
Total assets Rs m30,62084,816 36.1%  
Interest coverage xNM64.9-  
Debt to equity ratio x00.5 0.2%  
Sales to assets ratio x0.90.4 223.7%   
Return on assets %12.310.7 114.7%  
Return on equity %21.922.1 98.9%  
Return on capital %33.619.0 176.9%  
Exports to sales %030.7 0.0%   
Imports to sales %15.120.4 73.8%   
Exports (fob) Rs m410,717 0.0%   
Imports (cif) Rs m4,2377,105 59.6%   
Fx inflow Rs m51911,789 4.4%   
Fx outflow Rs m8,3208,393 99.1%   
Net fx Rs m-7,8013,396 -229.7%   
CASH FLOW
From Operations Rs m1,3865,264 26.3%  
From Investments Rs m5,010-9,540 -52.5%  
From Financial Activity Rs m-6,38310,867 -58.7%  
Net Cashflow Rs m126,591 0.2%  

Share Holding

Indian Promoters % 0.0 40.4 -  
Foreign collaborators % 50.7 20.6 246.1%  
Indian inst/Mut Fund % 10.2 8.4 121.4%  
FIIs % 23.8 10.7 222.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 19.9 77.4%  
Shareholders   102,036 109,995 92.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   PLETHICO PHARMA  DIVIS LABORATORIES  ASTRAZENECA PHARMA  SUN PHARMA  IPCA LABS  

Compare GSK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Biocon: High Other Income And Licensing Income Drive Growth (Quarterly Results Update - Detailed)

Nov 7, 2016

Biocon has announced its 2QFY17. The company has reported 19.8% YoY growth in net sales and profits of Rs 1.5 bn for the quarter. Here is our analysis of the results.

Biocon: Lower R&D Expenses Help Margin Expansion (Quarterly Results Update - Detailed)

Sep 19, 2016

Biocon has announced its 1QFY17. The company has reported 21.1% YoY growth in total income and 34.6% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Aug 18, 2017 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA - ASTRAZENECA PHARMA COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS